Sifap ("stroke in young Fabry patients") is a Pan-European study dedicated to investigating the correlation of juvenile stroke and a genetic disorder known as Fabry's disease. It was initiated by University of Rostock, Germany. [1] In recruiting 5,000 patients aged 18 to 55 it will be the largest study on stroke in the young. Approximately 50 study centres from about 15 European countries are participating in the project. The study is divided into two parts: sifap1 and sifap2. Whereas sifap1 analyses the frequency of Fabry disease within the patient cohort, sifap2 controls and investigates the rehabilitation phase of diagnosed Fabry patients.
The goal of the study is to show that Fabry disease has to be considered to be one of the most frequent genetic causes of juvenile stroke. To date the frequency of Fabry disease among general population has been estimated to be around 1:40,000. However, recent investigations have shown that Fabry disease can occur in 1 of 83 stroke patients aged 18–55 and between 1 of 3,500 to 1 of 4,500 individuals of the general population. Sifap aims at scientifically testing and supporting these findings.
After the proof-of-principle phase (April to December 2007) the official start of the study was January 1, 2008. Sifap1 patients were recruited until June 30, 2009. Sifap2 runs simultaneously, and is scheduled to conclude on June 30, 2012.
One of sifap’s unique characteristics is the fully automated analysis and storage of specimens in combination with the complete digital and web-based data handling. A pipetting robot extracts DNA from specimens and analyses them for Fabry disease. Afterwards, specimens are automatically stored in a biobank and consequently are available for future investigations.
In order to control, advise and establish professional structures two committees were formed. Publication issues and sifap basics are the responsibility of the steering committee. The nine members are: Miron Ginsberg (Miami, USA), Michael Hennerici (Mannheim, Germany), Christof Kessler (Greifswald, Germany), Edwin Kolodny (New York, USA), Peter Martus (Berlin, Germany), Bo Norrving (Lund, Sweden), Erich-Bernd Ringelstein (Münster, Germany), Peter Rothwell (Oxford, UK) and Graham Vanables (Sheffield, UK) The biobank committee oversees the administration of stored specimens and decides in formal meetings on proposed new projects. The biobank committee consists of: Natan Bornstein (Tel Aviv, Israel), Peter Paul DeDeyn (Antwerp, Belgium), Martin Dichgans (Munich, Germany), Franz Fazekas (Graz, Austria), Hugh Markus (London, UK), Olaf Rieß (Tübingen, Germany) and Arndt Rolfs (Rostock, Germany). Imaging analysis was centrally performed at the Department of Neurology of the Medical University of Graz, coordinated by Franz Fazekas.
| Country | City | Institution |
|---|---|---|
| Belgium | Antwerp | Middelheim General Hospital |
| Belgium | Leuven | UZ Gasthuisburg Hospital |
| Germany | Altenburg | Kreiskrankenhaus Altenburg |
| Germany | Bayreuth | Klinikum Hohe Warte |
| Germany | Berlin | Charité |
| Germany | Berlin | Klinikum Neukölln |
| Germany | Bremen | Klinikum Bremen Mitte |
| Germany | Celle | Allgemeines Krankenhaus Celle |
| Germany | Chemnitz | Klinikum Chemnitz |
| Germany | Dresden | Universitätsklinikum Carl Gustav Carus |
| Germany | Düsseldorf | Heinrich-Heine-Universität |
| Germany | Frankfurt | Johann-Wolfgang-Goethe-Universität |
| Germany | Giessen | Universität Giessen |
| Germany | Greifswald | Ernst-Moritz-Arndt-Universität |
| Germany | Halle/Saale | Martin-Luther-Universität |
| Germany | Hamburg | Universitätsklinikum Hamburg-Eppendorf |
| Germany | Heidelberg | Universität Heidelberg |
| Germany | Jena | Universitätsklinikum Jena |
| Germany | Kiel | Universitätsklinikum Schleswig-Holstein |
| Germany | Leipzig | Universitätsklinikum Leipzig |
| Germany | Marburg | Universitätsklinikum Giessen und Marburg |
| Germany | Mühlhausen | Ökumenisches Hainich Klinikum |
| Germany | Munich | Klinikum München - Großhadern |
| Germany | Münster | Universitätsklinikum Münster |
| Germany | Regensburg | Universitätsklinikum Regensburg |
| Germany | Rostock | Universität Rostock |
| Germany | Tübingen | Eberhard-Karls-Universität |
| Germany | Ulm | Universität Ulm |
| France | Lyon | Hospices Civils de Lyon |
| Finland | Helsinki | Helsinki University Central Hospital |
| Georgia | Tbilisi | S.Khechinashvili University |
| Republic of Ireland | Dublin | The Adelaide and Meath Hospital |
| Italy | Milan | Ospedale Maggiore Policlinico |
| Croatia | Zagreb | University Hospital "Sestre Milosrdnice" |
| Malta | Msida | St. Anne's Clinic |
| Austria | Graz | Universitätsklinik für Neurologie |
| Austria | Innsbruck | Universitätsklinik für Neurologie |
| Austria | Klagenfurt | LKH |
| Austria | Salzburg | Christian Doppler Klinik |
| Austria | Vienna | Krankenhaus der Barmherzigen Brüder |
| Austria | Linz | Wagner-Jauregg Linz |
| Poland | Warsaw | Institute of Psychiatry and Neurology |
| Portugal | Lisbon | Hospital de Sao José |
| Spain | Madrid | Hospital Universitario La Paz |
| United Kingdom | Glasgow | University of Glasgow |
| United Kingdom | Oxford | University of Oxford |
Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments and known interventions that warrant further study and comparison. Clinical trials generate data on dosage, safety and efficacy. They are conducted only after they have received health authority/ethics committee approval in the country where approval of the therapy is sought. These authorities are responsible for vetting the risk/benefit ratio of the trial—their approval does not mean the therapy is 'safe' or effective, only that the trial may be conducted.
Lysosomal storage diseases are a group of over 70 rare inherited metabolic disorders that result from defects in lysosomal function. Lysosomes are sacs of enzymes within cells that digest large molecules and pass the fragments on to other parts of the cell for recycling. This process requires several critical enzymes. If one of these enzymes is defective due to a mutation, the large molecules accumulate within the cell, eventually killing it.
Fabry disease, also known as Anderson–Fabry disease, is a rare genetic disease that can affect many parts of the body, including the kidneys, heart, and skin. Fabry disease is one of a group of conditions known as lysosomal storage diseases. The genetic mutation that causes Fabry disease interferes with the function of an enzyme that processes biomolecules known as sphingolipids, leading to these substances building up in the walls of blood vessels and other organs. It is inherited in an X-linked manner.
UK Biobank is a large long-term biobank study in the United Kingdom (UK) which is investigating the respective contributions of genetic predisposition and environmental exposure to the development of disease. It began in 2006.
Batten disease is a fatal disease of the nervous system that typically begins in childhood. Onset of symptoms is usually between 5 and 10 years of age. Often, it is autosomal recessive. It is the common name for a group of disorders called the neuronal ceroid lipofuscinoses (NCLs).
Metachromatic leukodystrophy (MLD) is a lysosomal storage disease which is commonly listed in the family of leukodystrophies as well as among the sphingolipidoses as it affects the metabolism of sphingolipids. Leukodystrophies affect the growth and/or development of myelin, the fatty covering which acts as an insulator around nerve fibers throughout the central and peripheral nervous systems. MLD involves cerebroside sulfate accumulation. Metachromatic leukodystrophy, like most enzyme deficiencies, has an autosomal recessive inheritance pattern.
A lipid storage disorder is any one of a group of inherited metabolic disorders in which harmful amounts of fats or lipids accumulate in some body cells and tissues. People with these disorders either do not produce enough of one of the enzymes needed to metabolize and break down lipids or, they produce enzymes that do not work properly. Over time, the buildup of fats may cause permanent cellular and tissue damage, particularly in the brain, peripheral nervous system, liver, spleen, and bone marrow.
Stargardt disease is the most common inherited single-gene retinal disease. In terms of the first description of the disease, it follows an autosomal recessive inheritance pattern, which has been later linked to bi-allelic ABCA4 gene variants (STGD1). However, there are Stargardt-like diseases with mimicking phenotypes that are referred to as STGD3 and STGD4, and have a autosomal dominant inheritance due to defects with ELOVL4 or PROM1 genes, respectively. It is characterized by macular degeneration that begins in childhood, adolescence or adulthood, resulting in progressive loss of vision.
A biobank is a type of biorepository that stores biological samples for use in research. Biobanks have become an important resource in medical research, supporting many types of contemporary research like genomics and personalized medicine.
Orphanet is a knowledge base dedicated to rare diseases as well as corresponding diagnosis, orphan drugs, clinical trials and expert networks
Sir Rory Edwards Collins FMedSci FRS is a British physician who is Professor of Medicine and Epidemiology at the Clinical Trial Service Unit within the University of Oxford, the head of the Nuffield Department of Population Health and a Fellow of Green Templeton College, Oxford. His work has been in the establishment of large-scale epidemiological studies of the causes, prevention and treatment of heart attacks, other vascular disease, and cancer, while also being closely involved in developing approaches to the combination of results from related studies ("meta-analyses").
Generation Scotland is a Biobank, a resource of biological samples and information on health and lifestyle from thousands of volunteer donors in Scotland.
The Albrecht Kossel Institute for Neuroregeneration is a medical research hospital located in Rostock, Germany. It was formed from the neurobiological laboratory of the hospital for neurology at the University of Rostock, and it operates under the auspices of The University Clinic of Rostock.
Return of results is a concept in research ethics which describes the extent of the duty of a researcher to reveal and explain the results of research to a research participant.
The Coriell Institute for Medical Research is an independent, non-profit biomedical research center dedicated to the study of the human genome. Coriell features programs in biobanking, personalized medicine, cell biology, cytogenetics, genotyping, and induced pluripotent stem cell science. Located in downtown Camden, New Jersey, the Institute has partnered with several prominent state and national health leaders, including Cooper University Hospital, the Cooper Medical School of Rowan University, the United States Air Force, the University of Pennsylvania, and Stanford University.
Catherine Sudlow is a British neurologist. She is a professor of Neurology and Clinical Epidemiology and Head of the Centre for Medical Informatics at the Usher Institute of Population Health Sciences and Informatics at the University of Edinburgh. She is the Chief Scientist of UK Biobank, and an honorary Consultant Neurologist in the Division of Clinical Neurosciences in Edinburgh.
Louise V. Wain is a British genetic epidemiologist currently serving as the British Lung Foundation Chair in Respiratory Research at the University of Leicester. Her research considers idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. During the COVID-19 pandemic, Wain studied the long-term impacts of COVID-19.
Franz Fazekas is an Austrian neurologist and former head of the department of neurology at the Medical University of Graz.
Georg Bernhard Landwehrmeyer FRCP is a German neurologist and neuroscientist in the field of neurodegeneration primarily focusing on Huntington's disease. Landwehrmeyer is a professor of neurology at Ulm University Hospital. He was one of the founders of the European Huntington's Disease Network (EHDN) in 2004 and was chairman of its executive committee until 2014.